Centessa Pharmaceuticals plc

NasdaqGS:CNTA Stock Report

Market Cap: US$2.2b

Centessa Pharmaceuticals Future Growth

Future criteria checks 0/6

Centessa Pharmaceuticals is forecast to grow earnings and revenue by 16.9% and 69.9% per annum respectively. EPS is expected to grow by 20% per annum. Return on equity is forecast to be -64.3% in 3 years.

Key information

16.9%

Earnings growth rate

20.0%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate69.9%
Future return on equity-64.3%
Analyst coverage

Low

Last updated20 Dec 2024

Recent future growth updates

Recent updates

Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring

Dec 31

Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?

Nov 14
Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

Sep 25

Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Aug 15
Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Apr 24

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Mar 07
Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Centessa Pharmaceuticals snaps multi-day losing streak; up 10%

Oct 20

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

Sep 14

Centessa Pharmaceuticals GAAP EPS of -$0.69

Aug 10

Checking In On Centessa Pharmaceuticals

Dec 23

Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high

Jun 14

Earnings and Revenue Growth Forecasts

NasdaqGS:CNTA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-245-212-2544
12/31/20269-213-183-2175
12/31/2025N/A-187-160-1775
12/31/2024N/A-173-160-1596
9/30/20247-161-130-130N/A
6/30/20247-157-146-146N/A
3/31/20247-138-150-150N/A
12/31/20237-151-161-160N/A
9/30/2023N/A-157-182-181N/A
6/30/2023N/A-173-183-183N/A
3/31/2023N/A-212-199-198N/A
12/31/2022N/A-216-202-201N/A
9/30/2022N/A-234-201-205N/A
6/30/2022N/A-220-195-199N/A
3/31/2022N/A-197-169-173N/A
12/31/2021N/A-381-136-136N/A
9/30/2021N/A-324-88-83N/A
6/30/2021N/A-286-56-52N/A
3/31/2021N/A-246-24-20N/A
12/31/2020N/A-11-11-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNTA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CNTA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CNTA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CNTA is forecast to have no revenue next year.

High Growth Revenue: CNTA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CNTA is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 08:17
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Centessa Pharmaceuticals plc is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.